MA44762A - Sémaglutide utilisé dans le traitement de maladies cardiovasculaires - Google Patents

Sémaglutide utilisé dans le traitement de maladies cardiovasculaires

Info

Publication number
MA44762A
MA44762A MA044762A MA44762A MA44762A MA 44762 A MA44762 A MA 44762A MA 044762 A MA044762 A MA 044762A MA 44762 A MA44762 A MA 44762A MA 44762 A MA44762 A MA 44762A
Authority
MA
Morocco
Prior art keywords
semaglutide
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
MA044762A
Other languages
English (en)
Inventor
Oluf Kristian Højbjerg Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44762(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA44762A publication Critical patent/MA44762A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
MA044762A 2016-04-28 2017-04-28 Sémaglutide utilisé dans le traitement de maladies cardiovasculaires MA44762A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12

Publications (1)

Publication Number Publication Date
MA44762A true MA44762A (fr) 2019-03-06

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044762A MA44762A (fr) 2016-04-28 2017-04-28 Sémaglutide utilisé dans le traitement de maladies cardiovasculaires

Country Status (24)

Country Link
US (3) US12569543B2 (fr)
EP (1) EP3448416B1 (fr)
JP (1) JP7221694B2 (fr)
KR (3) KR20180135012A (fr)
CN (1) CN109069589B (fr)
AU (2) AU2017256774B2 (fr)
BR (1) BR112018072020A2 (fr)
CA (1) CA3022535A1 (fr)
CL (1) CL2018003045A1 (fr)
DK (1) DK3448416T3 (fr)
ES (1) ES2928007T3 (fr)
HR (1) HRP20221150T1 (fr)
HU (1) HUE060040T2 (fr)
IL (1) IL262390B1 (fr)
MA (1) MA44762A (fr)
MX (1) MX2018012700A (fr)
MY (1) MY202967A (fr)
PH (1) PH12018502274B1 (fr)
PL (1) PL3448416T3 (fr)
RS (1) RS63630B1 (fr)
RU (1) RU2768283C2 (fr)
SI (1) SI3448416T1 (fr)
WO (1) WO2017186896A1 (fr)
ZA (2) ZA202507395B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180135012A (ko) 2016-04-28 2018-12-19 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
MA54510A (fr) * 2018-12-21 2022-03-30 Novo Nordisk As Procédé de séchage par pulvérisation de peptide glp-1
BR112022013795A2 (pt) * 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
CN119317635A (zh) * 2022-06-08 2025-01-14 载度思生命科学有限公司 用于2型糖尿病和体重管理的可重复使用的多剂量可变剂量的单一笔式注射器
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412384B1 (fr) * 2001-06-28 2007-12-26 Novo Nordisk A/S Formulation stable de glp-1 modifie
JP2005535569A (ja) 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2942185T3 (es) 2009-10-02 2023-05-30 Boehringer Ingelheim Int Composiciones farmacéuticas que comprenden BI-1356 y metformina
EP2504002B1 (fr) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Traitement de patients diabétiques génotypés par des inhibiteurs de dpp-iv tels que la linagliptine
KR101927068B1 (ko) * 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX345501B (es) * 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2014066992A1 (fr) 2012-11-02 2014-05-08 Mansoor Husain Procédés d'inhibition de l'agrégation de plaquettes utilisant d'agonistes du récepteur de glp-1
WO2014124860A1 (fr) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Inhibiteurs spécifiques de pde4b pour le traitement du diabète sucré
WO2014140284A1 (fr) 2013-03-15 2014-09-18 Boehringer Ingelheim International Gmbh Utilisation de linagliptine dans le traitement antidiabétique cardio- et néphroprotecteur
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA2981507A1 (fr) 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Compositions pharmaceutiques pour therapie combinee
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
KR20180135012A (ko) 2016-04-28 2018-12-19 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드

Also Published As

Publication number Publication date
RU2018140900A (ru) 2020-05-28
PH12018502274A1 (en) 2019-09-09
KR20250038818A (ko) 2025-03-19
US12569543B2 (en) 2026-03-10
PH12018502274B1 (en) 2024-02-28
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
EP3448416B1 (fr) 2022-08-10
AU2024227113A1 (en) 2024-10-31
RU2768283C2 (ru) 2022-03-23
CL2018003045A1 (es) 2018-12-14
CA3022535A1 (fr) 2017-11-02
KR20180135012A (ko) 2018-12-19
PL3448416T3 (pl) 2022-11-07
ES2928007T3 (es) 2022-11-14
US20250288649A1 (en) 2025-09-18
CN109069589A (zh) 2018-12-21
MX2018012700A (es) 2019-01-30
BR112018072020A2 (pt) 2019-02-12
HUE060040T2 (hu) 2023-01-28
MY202967A (en) 2024-05-31
RS63630B1 (sr) 2022-10-31
KR102778218B1 (ko) 2025-03-10
EP3448416A1 (fr) 2019-03-06
WO2017186896A1 (fr) 2017-11-02
US20250262281A1 (en) 2025-08-21
IL262390A (en) 2018-12-31
ZA202507394B (en) 2025-09-25
JP7221694B2 (ja) 2023-02-14
AU2017256774A1 (en) 2018-11-01
DK3448416T3 (da) 2022-10-03
KR20220147712A (ko) 2022-11-03
AU2017256774B2 (en) 2024-07-11
CN109069589B (zh) 2022-09-06
RU2018140900A3 (fr) 2020-09-28
HRP20221150T1 (hr) 2022-11-25
SI3448416T1 (sl) 2022-10-28
ZA202507395B (en) 2025-09-25
JP2019514925A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
IL279752B (en) Polycyclic compounds and use thereof in the treatment of immune disorders
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3359171C0 (fr) Utilisation d'akkermansia muciniphila pour traiter des états inflammatoires
EP3370748A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
EP3960735C0 (fr) Dérivés de quinazoline utilisés pour traiter le vih
EP3448263A4 (fr) Traitement électrothérapeutique
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
PT3681857T (pt) Fluorofenil-beta-hidroxietilaminas e sua utilização no tratamento de hiperglicemia
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
IL270978B (en) Grape skin for use in the treatment of dysbiosis
HUE062784T2 (hu) Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében
EP3678692A4 (fr) Stratification du génotype dans le traitement et la prévention du diabète
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
EP3426307A4 (fr) Utilisation de dreadd pour la modulation neuronale dans le traitement de maladies neuronales
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d'infections
EP3431517A4 (fr) Copolymère, et agent de traitement de surface
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
EP3395341A4 (fr) Composition pour le traitement de maladies neuromotrices et son utilisation
EP3397063A4 (fr) Utilisation de microbulles et de nanobulles dans le traitement de liquide